Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2020

Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice

Résumé

Hepatitis B virus (HBV) affects an estimated 250 million chronic carriers worldwide. Though several vaccines exist, they are ineffective for those already infected. HBV persists due to the formation of covalently closed circular DNA (cccDNA)-the viral minichromosome-in the nucleus of hepatocytes. Current nucleoside analogs and interferon therapies rarely clear cccDNA, requiring lifelong treatment. Our group identified GLP-26, a novel glyoxamide derivative that alters HBV nucleocapsid assembly and prevents viral DNA replication. GLP-26 exhibited single-digit nanomolar anti-HBV activity, inhibition of HBV e antigen (HBeAg) secretion, and reduced cccDNA amplification, in addition to showing a promising preclinical profile. Strikingly, long term combination treatment with entecavir in a humanized mouse model induced a decrease in viral loads and viral antigens that was sustained for up to 12 weeks after treatment cessation.
Fichier principal
Vignette du fichier
Antimicrobial Agents and Chemotherapy-2019-Amblard-AAC.01701-19.full.pdf (876.11 Ko) Télécharger le fichier
Loading...

Dates et versions

pasteur-02875583 , version 1 (19-06-2020)

Licence

Paternité - Pas d'utilisation commerciale - Partage selon les Conditions Initiales

Identifiants

Citer

Franck Amblard, Sébastien Bouclé, Leda Bassit, Bryan Cox, Ozkan Sari, et al.. Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice. Antimicrobial Agents and Chemotherapy, 2020, 64 (2), ⟨10.1128/AAC.01701-19⟩. ⟨pasteur-02875583⟩
62 Consultations
455 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More